Patrick Grossmann

Entrepreneur and Scientist I CEO & Co-Founder of Invitris (YC W23) I Former Harvard Medical School & ETH Zurich

Co-founder

Invitris· Winter 2023🇩🇪 Bavaria, Germany

in LinkedIn

2022Co-founder· Invitris

Founder · since 2022

Company

Invitris

Role

CEO & Co-Founder

current

Stage

—

no public source

Raised

—

no public source

Based

Munich, Bavaria, Germany

current

Founder / co-founder — the company's markEmployee / research role

Source: LinkedIn work history

Profile coverage5 of 7 · missing posts, contact

Invitris

Creating new protein-based drugs at scale

Winter 2023

Experience

Career

Invitris
Co-founder
CEO & Co-Founder · Munich, Bavaria, Germany · 2022 – Present
2022
Patrick Grossmann - Freelancing Services
Bioinformatics Freelancer · Munich Area, Germany · 2019 – Present
2019
DEOXY
Head of Business Development, GO-Bio Funded · Munich Area, Germany · 2019 – 2020
2019
The Linde Group
Product Manager · Munich Area, Germany · 2018 – 2019
2018
The Linde Group
Digital Strategy · Munich Area, Germany · 2017 – 2018
2017
Harvard University
Researcher · Greater Boston Area · 2014 – 2017
2014
Dana-Farber Cancer Institute
Doctoral Researcher · Greater Boston Area · 2014 – 2017
2014
ETH Zurich
Visiting Graduate Student · Basel Area, Switzerland · 2013 – 2014
2013
University of Bielefeld
Graduate Student · Bielefeld Area, Germany · 2011 – 2014
2011
Dana-Farber Cancer Institute
Bioinformatics Trainee · Greater Boston Area, USA · 2013
2013
Computational Metagenomics Group, University of Bielefeld
Graduate Research Assistant · Bielefeld Area, Germany · 2012
2012
Network Operation Center, University of Bielefeld
Student Research Assistant · Bielefeld Area, Germany · 2010 – 2012
2010
ETH Zurich
Visiting Undergraduate Student · Basel Area, Switzerland · 2011
2011

Bio

My hearts are entrepreneurship & science, originally trained as bioinformatician at the Harvard Medical School and ETH Zurich amongst other schools. I earned a PhD and MBA, and highly enjoy opportunities to improve the world with science-based products. I co-founded Invitris to radically simplify drug development to stop antibiotic-resistance, which has the potential to become the dominating health-economic challenge in this century.